Adherence and Persistence to Inclisiran Among Early Users in Germany

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05870657

Enrollment

1109

Registered

2023-05-23

Start date

2022-02-16

Completion date

2022-05-12

Last updated

2023-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High Levels of Low-density Lipoprotein Cholesterol

Brief summary

The present study was a descriptive, non-interventional, retrospective cohort study aimed at evaluating early data on adherence, persistence, and treatment patterns among patients receiving inclisiran and other lipid-lowering therapies (LLT) in a real-world setting in Germany. Analysis was carried out using the IQVIA™ LRx database.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Study subjects ≥18 years old who were prescribed an inclisiran dose.

Exclusion criteria

None

Design outcomes

Primary

Measure	Time frame
Number and percentage of patients with at least 5 months of potential follow-up who were prescribed a second dose of inclisiran	8 months
Percentage of patients who were prescribed a second dose of inclisiran between 1 and 6 months after prescription of first dose	8 months
Median time between first and second prescribed doses	8 months

Secondary

Measure	Time frame
Age and gender characteristics	6 months
Age and gender distribution	6 months
Prescriber specialty distribution for patients	6 months

Countries

Switzerland

Outcome results